TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Urinary excretion of C-terminal cross-linking telopeptides of type I collagen (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Potassium Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Body Potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Access Rate POST
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recommendation Rate POST
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction Rate POST
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete response rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in COX-2 dependent urinary PGE-M production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive bio-markers for chronic Graft-Versus-Host Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: disease control rate (DCR) at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma and Whole Blood Concentration for Pevonedistat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: Time to Reach the Maximum Plasma and Whole Blood Concentration (Cmax) for Pevonedistat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast: Area Under the Plasma and Whole Blood Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Pevonedistat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echocardiographic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Kinematic functional shoulder scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reintubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: In Hospital Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Upper Limb Fugl Meyer Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOFA score value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E/e'/LV end-diastolic volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Elastographic Value in kPa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of total radioactivity in blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of radioactive dose in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of radioactive dose in faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Attendance at initial CR orientation appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in anxiety levels as measured by the Screen for Child Anxiety Related Disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in thermic effect of food
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Center of Pressure Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Pain Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Ocular Surface Disease Index (OSDI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hippocampal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Initial Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma Concentration versus Time Curve (AUC) of Tesamorelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Tesamorelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin-like Growth Factor-1 (IGF-1) Level at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease specific health-related quality of life (HRQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post operative narcotic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete and Partial Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lymphocyte subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of Negative Pressure Wound Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Worsening of OCT measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical Power (MP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Perceived strength of taste for bitter and sweet tastes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 28
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 52/End of Study (EOS)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 52/End of Study (EOS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Plasma Functional Alpha-1 Antitrypsin (AAT) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of active disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of severe disease (presence of ulceration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of bacterial resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nocturnal Urinary Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Rivermead Mobility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Timed Up and Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Patient Specific Functional Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Physical Activity Diary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Physical activity - 7-day accelerometry
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity of EBV associated biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of EBV associated biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of EBV associated biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of EBV associated biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin microcirculation post occlusive reactive hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin microcirculation acetylcholine induced dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean LH frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in parental emotion dysregulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in child behavior
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Change in parenting Quality
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: SAEs and AEs G3
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of metastases to axillary lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Freedom From Molecular Residual Disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Who Were Disease-Free for at Least 12 Months After Initial Diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Were Disease-Free for at Least 24 Months After Initial Diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Disease-Free Interval
Endpoint domain: Mortality/survival
Primary endpoint: fMRI resting state functional connectivity (RSFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of preemptive surgical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of preemptive surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Adverse Events Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of biomarkers S100B and NSE in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: myocardial diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: arterial partial pressure of oxygen divided by fraction of inspired oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median Proportion Cells That Are Apoptotic in Epithelial Ovarian Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Adverse Events According to Grade as Determined by NCI CTCAE v.3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Days of Unhealthy Alcohol Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery Experiences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Airway Seal Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection of genomic alterations in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Adverse Events During the Trial
Endpoint domain: Adverse events/effects
Primary endpoint: Anxiety assessed by Children's State Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mean Plasma Glucose (MPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole-body Glucose Utilization (Rd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tissue of origin predicted by RT-PCR assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Insulin Therapy Post Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estimated Glomerular Filtration Rate (eGFR) 1 Year Following Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Frequency which induces Dynamic Hyperinflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and Specificity of atrial fibrillation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Orthoptic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of the trans anal irrigation (TAI) procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Willingness to Participate and Program Adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Emergency level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cefazolin blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of MRIs Correctly Identifying Clinically Important Intracranial Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiopulmonary Exercise Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completion of Genetic Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accumulated Hb and bilirubin in CSF drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Donor registration status
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urine output of sodium, potassium and chloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage achieving 100 Personal Activity Intelligence points (PAIs) per week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diffusion capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clubhead speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite CVD Goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of influenza-like illnesses (ILI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative endodontic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in SBP and DBP at the Indicated Time Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes From Baseline in Cognition as Measured by the Leiter-R at the Indicated Time Points
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of eligible patients screened for unhealthy alcohol use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of screen positive patients who received brief counseling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of screen positive patients who received MAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of screen positive patients referred to specialty clinics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of screen positive patients who received any treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated cost of providing virtual practice transformation support
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: International Restless Legs Syndrome Rating Scale (IRLS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sedation/drowsiness
Endpoint domain: Adverse events/effects
Primary endpoint: Brief Alcohol Counseling Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: tumor necrosis factor (TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Abdominal Pain Intensity (API) Weekly Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oral Intake in ml/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck and Shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral arterial disease (PAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abdominal aortic aneurysm (AAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac arrythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metabolic control (measured by HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic accuracy of composite measure (serum CA 125 levels and VAS pain score changes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine peroxides concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Illness Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful placement of device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maternal endothelial health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiovascular disease events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: successful insertion of laryngeal mask
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Healing of meniscus suturing area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Completed 8 Cycles
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Limitation of caloric deficit (Intake to Need Deviation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hsPCR (high-sensitivity C-reactive protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of KRN330
Endpoint domain: Adverse events/effects
Primary endpoint: Protection rate of the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal Increase in Serum Sodium Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time of Maximal Increase in Serum Sodium Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Achieved of Major Molecular Response (MMR) or Complete Molecular Response (CMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-Meter Walk test (10MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time within predefined SpO2 target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of topiramate and naltrexone combination
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of topiramate and naltrexone combination for alcoholism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Learning Achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in scores on the ASD Knowledge Quiz
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ultrasonography Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed recall (verbal memory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delayed recall (non-verbal memory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence of Cleared Treated AK Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: T1 mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achilles Peritendinous Amino Acid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in glycosylated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recommended dose of BAY 43-9006 (SORAFENIB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of Life in Epilepsy Inventory (QOLIE-31)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual acuity 20/70 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes